Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904517 | 1.00 | KDM1A (0.50) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL216035 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL20552191 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL693557 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL6682662 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL123151 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL1053630 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL8361882 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL235344 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 | |
| SCHEMBL5699292 | 0.98 | KDM1A (0.48) | KDM1AMAPTHDAC2HDAC1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022202333-A1 | PHENOLIC RESIN MIXTURE, AND CURABLE RESIN COMPOSITION AND CURED PRODUCT THEREOF | 日本化薬株式会社 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022202335-A1 | PHENOLIC RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | 日本化薬株式会社 | 2022-09-29 | — | — | WO | disclosed |
| US-10117878-B2 | Ligands for nematode nuclear receptors and uses thereof | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-06 | — | — | US | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | disclosed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | disclosed |
| EP-2555775-B1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1523568-A2 | MICROBIOLOGICAL METHOD FOR THE PRODUCTION OF 7 ALPHA-SUBSTITUTED 11 ALPHA-HYDROXYSTEROIDS | Schering Aktiengesellschaft (DE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004011663-A9 | MICROBIOLOGICAL METHOD FOR THE PRODUCTION OF 7 ALPHA-SUBSTITUTED 11 ALPHA-HYDROXYSTEROIDS | SCHERING AG (DE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004011663-A2 | MICROBIOLOGICAL METHOD FOR THE PRODUCTION OF 7 ALPHA-SUBSTITUTED 11 ALPHA-HYDROXYSTEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | WO | disclosed |
| EP-0711313-A1 | ISOCYANATE/POLYOL REACTION RESIN | Henkel Kommanditgesellschaft auf Aktien (DE) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995000568-A1 | ISOCYANATE/POLYOL REACTION RESIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1995-01-05 | — | — | WO | disclosed |
| EP-0506359-A2 | Epoxy resin compositions and semiconductor devices encapsulated therewith | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10117878-B2 | Ligands for nematode nuclear receptors and uses thereof | NR4A1, NR0B1, NR1H2 | KDM1A 2231/4885MAPT 4726/4885HDAC2 543/4885 |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | KDM1A 1944/4885MAPT 3482/4885HDAC2 1956/4885 |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | PTGIR, ADORA1, PDE3A | KDM1A 1060/4885MAPT 4697/4885HDAC2 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.